“showed a trend”

Consistent with this, blocking GM-CSF showed a trend ( n = 5, P = 0.0625) toward partial rescue of the decrease in monocyte frequency induced by peanut protein in PA participants ( Fig.

GHRHRs were more abundant in the border zones compared with their infarct zones in both GHRH‐A and placebo groups (73.5±8.1 versus 204.2±4.5 and 105.2±10.9 versus 196.3±2.3, respectively; P <0.0001 for both by Kruskal–Wallis test) ( Figure 6 B), and the GHRH‐A group showed a trend toward higher levels in the border zones ( P <0.0625 versus placebo by Wilcoxon rank test) than did the placebo group ( Figure 6 C).

The frequency of classical (CD14 + ) monocytes showed a trend to decrease ( p = 0.0625) during the first 20 weeks after vaccination, while the frequency of non-classical monocytes, which are involved in T-cell stimulation and inflammatory cytokine release ( 38 ), showed a trend ( p = 0.0625) to increase over the same period of time.

Blinded histopathological analyses were performed to validate the TME signature data, revealing that Cluster B showed a trend toward a non‐brisk classification ( p = 0.0625) and a lower percentage of immune cells ( p = 0.079).

Subjects receiving abatacept showed a trend toward improvement in mRSS at week 24 (−8.6 ± 7.5, p = 0.0625) while those in the placebo group did not (−2.3 ± 15, p = 0.75).

However, Bacteroides vulgatus showed a trend toward increased abundance (mean difference: 0.0968; p = 0.0625), while Escherichia coli showed a decrease (mean difference: 1.62; p = 0.100).

As in the ITT population [ 4 , 13 ], patients in the biomarker subset receiving sunitinib had significantly longer PFS than those receiving IFN-α [median PFS 13.7 vs 5.1 months; hazard ratio 0.293 (95 % confidence interval or CI 0.129–0.665); P = 0.0021]; sunitinib patients in the biomarker subset also showed a trend for improved OS compared with IFN-α patients [median OS not reached vs 18.3 months; hazard ratio 0.509 (95 % CI 0.246–1.05); P = 0.0626].

12.9 months; p = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response ( p = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend ( p = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement.

Action potential firing elicited by current injection showed a trend toward increased excitability [repeated measures ANOVA, main effect treatment: F (1, 39) = 3.672, p = 0.0627; time F (7,273) = 62.99, p < 0.0001; time × drug F (7,273) = 1.237, p = 0.2825; Figure 4F ], and reduced latency for AP firing [repeated measures ANOVA, main effect treatment: F (1, 39) = 3.435, p = 0.0714; time F (7, 273) = 70.88, p < 0.001; time × drug F (7, 273) = 0.9778, p = 0.4476; Figure 4G ].

Though not significant, 12-month-aged rats showed a trend toward longer strides than 3-month-aged rats (Fig. 1 b; t (20) = 1.97, p = 0.0627), indicating that overall stepping patterns are altered with age.

Multivariate regression analysis of predictors of longer than 8 days admission found that a higher removed gland weight correlated with longer length of hospitalization (95% confidence interval [CI] 0.07–1.5526; P =0.0308) and elevated alkaline phosphatase showed a trend toward significant correlation (95% CI −0.0002 to 0.0092; P =0.0628) for the same outcome.

WST assay revealed that TMAO-activated PBMCs showed a trend toward enhanced cytotoxic activity against AN3CA cells ( p = 0.0628; Fig. 6 H), while no significant effect was observed in HEC-1B cells ( p = 0.6398; Fig. 6 G).

For tumors 5–10 cm, chemotherapy showed a trend toward improved survival (HR = 0.45, 95% CI: 0.19–1.05, p = 0.063).

With a two-layer setup, the devices showed moderate to very high correlations, except for the PACT, where the softest layer was on top but only showed a trend ( p = 0.063).

Post-hoc Tukey HSD mean comparisons revealed that ret+ext of the TL compound resulted in a significant decrease in freezing compared to the no ext group ( P = 0.028) and the T+L ext-only group showed a trend toward freezing reduction compared to the no ext group that was not significant ( P = 0.063).

The linear regression showed a trend with borderline significance between lifetime GAF and CYP2C19 metabolizer status association (ß = 3.5, 95% CI: −0.2–7.1; p = 0.063, Supplementary Table 1 ).

Progression-free survival Univariate analysis of the whole collective and of the matched-pair group showed a trend towards better progression-free survival for the patients treated with CIRT (5.5 months vs. 3.9 months, p = 0.063; for the propensity score-matched group 5.7 months vs. 3.9 months, p = 0.085).

The radiation treatment group (group 2) showed a trend towards lower eNOS mRNA expression than the control group (group 1 vs group 2, p = 0.063 after post hoc test), but daily PDE5I treatment lessened this decrease (group 2 vs. group 3, p = 0.063 after post hoc test) ( Fig 2C ).

Non-PDAC pathology also showed a trend toward increased risk (OR: 1.88, 95% CI: 0.98–3.76, p = 0.063).

Similarly, the Radiation Therapy Oncology Group (RTOG) #9501 trial showed a trend toward improved OS rates, albeit with marginal significance (OS rate of 42% with adjuvant CRT, compared to 31% with RT alone, p = 0.063).

Patients with QRS duration ≥150 ms showed a trend towards more LVESV change compared with <150 ms patients (−33 ± 24% vs. −6 ± 33%; P = 0.063).

Baseline 0800 h insulin concentrations (0 min DCP sample) also showed a trend towards being lower in treated ponies (P = 0.063), with a median (IQR) value of 8 μIU/mL (4–95) compared to 52 μIU/mL (10–189) for controls.

Regarding immune microenvironment analysis, patients with HCC in the high-risk score group showed a trend towards decreased stromal score ( P = 0.063), immune score ( P = 0.056), and estimate score ( P = 0.051), although the lack of significant differences may be attributed to the small sample size (Figure 8A–C ).

Participants following a long-term pattern with MDs showed significantly decreased plasma levels of MCP-1 ( p < 0.001, both), MIP-1β ( p < 0.031, both), ENA78 ( p < 0.001, both), IL-1β ( p < 0.025, both), IL-6 ( p < 0.013, both), IL-8 ( p < 0.025, both), IL-12p70 ( p = 0.022, MD-nuts), TNF-α ( p < 0.022, both), IFN-γ ( p < 0.040, both), and hs-CRP ( p < 0.018, both), while no significant changes were observed in these biomarkers in the LFD group ( p > 0.05), except for hs-CRP that showed a trend to reduction ( p = 0.063).

Patients with a longer diagnostic delay (>23.9 months) showed a trend towards higher proportion of low zinc levels (11/26, 42.3% versus 12/42, 22.2%, p = 0.063).